Invention Grant
- Patent Title: 1AP E3 ligase directed proteolysis targeting chimeric molecules
-
Application No.: US15568006Application Date: 2016-04-20
-
Publication No.: US10336744B2Publication Date: 2019-07-02
- Inventor: John David Harling , Ian Edward David Smith
- Applicant: GlaxoSmithKline Intellectual Property Development Limited
- Applicant Address: GB Brentford, Middlesex
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Brentford, Middlesex
- Agent Nora L. Stein; Fang Qian; Edward R. Gimmi
- Priority: GB1506871.1 20150422
- International Application: PCT/EP2016/058769 WO 20160420
- International Announcement: WO2016/169989 WO 20161027
- Main IPC: C07D417/14
- IPC: C07D417/14 ; A61K31/4725 ; A61K31/519 ; C07D417/12 ; C07D487/04 ; A61K47/54 ; A61K47/66

Abstract:
The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
Public/Granted literature
- US20180118733A1 lAP E3 LIGASE DIRECTED PROTEOLYSIS TARGETING CHIMERIC MOLECULES Public/Granted day:2018-05-03
Information query